Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: The changing treatment landscape for non-Hodgkin lymphoma

Andrew Zelenetz, Anton Hagenbeek and Franck Morschhauser • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Anton Hagenbeek, MD, PhD, of Academic Medical Center, Amsterdam, The Netherlands, chairs a discussion with Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, and Franck Morschhauser, MD, PhD, of Centre Hospitalier Régional Universitaire de Lille, Lille, France, on new options and new challenges associated with the development of targeted therapies for non-Hodgkin lymphoma. There is a focus on clinical trial design, which must continue to adapt to the increasing number of emerging targeted therapies in order to establish if and how these new approaches can be incorporated into standard clinical care.

More from Andrew Zelenetz

Novel lymphoma targets and agents
Andrew Zelenetz et al. • 8 Sep 2017
5:20
m7-FLIPI identifies patients with early disease progression of FL after therapy
Andrew Zelenetz • 4 Dec 2015
4:51
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz • 4 Dec 2015
2:33
ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz
Andrew Zelenetz • 4 Dec 2015

More from Anton Hagenbeek

23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
2:56
Immuno-oncology opportunities for the treatment of lymphoma
Anton Hagenbeek • 4 Dec 2015
2:18
Brentuximib vedotin therapy for Hodgkin lymphoma
Anton Hagenbeek • 9 Dec 2014
1:58
What should the future of cancer treatment and research look like?
Anton Hagenbeek • 9 Jun 2016

More from Franck Morschhauser

6:38
Follicular lymphoma: is RELEVANCE relevant?
Franck Morschhauser • 15 Jun 2018

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals